Large RAD51D screen clarifies cancer-linked variants

A large-scale experiment has assessed the functional impact of 6,888 coding changes in RAD51D, a tumour-suppressor gene required for homologous recombination. The study, reported by Nature Communications through nature.com, produced a map that distinguishes established disease-causing variants from variants known to be benign.

The findings also offer a clearer view of how different parts of RAD51D contribute to its activity. Changes affecting the protein’s DNA-binding region or its ATPase core were especially likely to impair homologous recombination. The researchers further identified an important contact between RAD51D and RAD51C in the BCDX2 complex, linking that interface to control of ATPase activity.

A problem of uncertain variants

Pathogenic RAD51D variants have been associated with breast and ovarian cancers. Yet most missense variants found in clinical testing have not been classified confidently. A missense variant changes one amino acid in a protein, but the presence of such a change does not by itself show whether the protein will continue to work normally.

That uncertainty creates a challenge for interpreting genetic results. Variants can be observed in patients without enough evidence to label them either harmful or harmless. The new work addresses that gap by testing RAD51D variants directly for loss of function rather than relying only on existing clinical observations or predictions based on sequence changes.

The researchers used a multiplex variant-effect assay to examine thousands of RAD51D coding variants in a single experimental framework. The resulting variant-to-function map separated the known pathogenic and benign variants in the study without overlap. This provides a functional reference for assessing the many RAD51D changes whose clinical meaning remains unclear.

The map was also checked against independent tests. Those orthogonal homologous-recombination and biochemical assays covered 70 clinical variants, providing a separate comparison for the screen’s results. Together, the experiments supported the ability of the large-scale assay to identify variants that compromise RAD51D function.

Damage concentrated in key protein regions

The pattern of results was not uniform across RAD51D. Variants in the DNA-binding portion had some of the strongest effects on homologous recombination, as did changes in the ATPase core. These results point to regions where alterations are particularly likely to interfere with the protein’s molecular role.

The study also focused on RAD51D’s partnership with RAD51C. The two proteins form part of the BCDX2 complex, and the researchers found that their interface is necessary for regulating the complex’s ATPase activity. This adds a structural and biochemical dimension to the variant map: some disease-associated changes may cause harm not simply by affecting an isolated region of RAD51D, but by disturbing how the protein works with its partner.

The identified areas of vulnerability amount to hotspots for deleterious RAD51D variants. They may help explain why some substitutions have a pronounced effect while others elsewhere in the protein are less disruptive. The findings connect the location of a variant with the specific biochemical function most likely to be affected.

A proposed role for RAD51D

The results led the researchers to propose an unexpected model for RAD51D within BCDX2. Rather than promoting the complex’s ATPase activity, RAD51D may primarily restrain it. In this interpretation, slowing the reaction would give RAD51 filament assembly adequate time and physical opportunity to take place.

That proposal remains a hypothesis, but it offers a possible explanation for the study’s biochemical observations. If RAD51D normally acts as a brake on ATPase activity, variants that disrupt its interaction with RAD51C or damage its core functional regions could alter the timing needed for filament formation. The resulting defect would be consistent with the loss of homologous-recombination activity measured in the experiments.

By combining a screen of thousands of variants with independent testing of clinical examples, the Nature Communications study provides both a classification resource and a mechanistic account of RAD51D dysfunction. Its results identify regions where harmful variants are concentrated and show how those changes can interfere with the protein’s biochemical functions.